Arjun Goyal
Co-founder @ Affini-T Therapeutics
Boston, United States
Arjun Goyal is a Co-Founder and Managing Director at Vida Ventures and a Co-founder at Affini-T Therapeutics. He has an MBA from Harvard Business School and University of Cambridge, a bachelor's degree from University of Oxford and University of Melbourne.
- Total investments:
- 12
- Last investment:
- Lead investor:
- 58%
Last updated:
For AI agents: llms.txt
Industries Arjun Goyal invests in
Stages Arjun Goyal invests in
Countries Arjun Goyal invests in
Investment Focus
Industry
- Biotechnology 7 (58%)
- Health Care 4 (33%)
- Therapeutics 4 (33%)
- Medical 3 (25%)
- Pharmaceutical 3 (25%)
Stage
- Series A 4 (33%)
- Series B 4 (33%)
- Series C 2 (17%)
- Series D 1 (8%)
- Venture - Series Unknown 1 (8%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Halda Therapeutics
|
Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states. | $126M / Series B / Aug 12, 2024 | |
Third Arc Bio
|
Third Arc Bio is a biotech company developing multifunctional antibodies for inflammatory and immunology diseases. Its drug development engine delivers superior biologics optimized to create T-cell engagement by leveraging two technologies that power a pipeline of high-value therapeutics – a solid tumor synergy platform and an I&I platformthat offers a novel approach to precision immune regulation at a tissue-specific level to achieve superior efficacy and safety. | $165M / Series A / Jul 23, 2024 | |
Scorpion Therapeutics
|
Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purposemodel to efficiently unlock the next generation of precision oncology. | $150M / Series C / Jul 16, 2024 | |
Alterome Therapeutics
|
Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. | $132M / Series B / Apr 03, 2024 | |
Quanta Therapeutics
|
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA. | $50.7M / Series D / May 22, 2023 | |
Affini-T Therapeutics
|
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-celltherapies designed to eradicate tumors. | $175M / Venture - Series Unknown / Mar 22, 2022 | |
|
Alterome Therapeutics
|
Alterome Therapeutics is a precision oncology biotech developing alteration-specific therapeutics to address high value and validated oncogenic drivers. | $64M / Series A / Jan 19, 2022 | |
|
Quanta Therapeutics
|
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates using allosteric modulation to target driver oncogenes. The company was founded in 2018 and is based in San Francisco, CA. | $60M / Series C / Oct 26, 2021 | |
Centessa Pharmaceuticals
|
Centessa Pharmaceuticals is a next-generation biopharmaceutical company that aims to reshape the traditional drug development process. The company applies an asset-centric R&D model at scale to advance a portfolio of highly validated programs led by industry-leading teams. Each program is developed by a Centessa Subsidiary and supported by acentralized infrastructure and the Centessa management team. | $250M / Series A / Feb 16, 2021 | |
|
Scorpion Therapeutics
|
Scorpion Therapeutics was founded to broaden the reach and impact of precision medicine to more people with cancer. The company is integrating cutting-edge technologies across target discovery, medicinal chemistry, and translational medicine to deliver Precision Oncology 2.0. Scorpion’s experienced leadership team is executing a fit-to-purposemodel to efficiently unlock the next generation of precision oncology. | $162M / Series B / Jan 07, 2021 | |
| See all 12 investments → | |||
Co-Investors
About Affini-T Therapeutics
Affini-T Therapeutics is a biotechnology company developing T-cell therapies for patients suffering from cancer. Affini-T uses a validated platform to select high-affinity T cell receptors specific to oncogenic mutations to pioneer cutting-edge solid tumor therapies. Affini-T leverages gene editing and synthetic biology to engineer novel T-celltherapies designed to eradicate tumors.
Affini-T Therapeutics Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Arjun Goyal
Co-founder
|
|||
Jak Knowles
Co-Founder, President and Chief Executive Officer
|
|||
Kathy Yi
Chief Operating Officer
|
|||
Kim Nguyen
Chief Technical Officer
|
|||
|
Loic Vincent
CSO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Arjun Goyal invest in?
Arjun Goyal invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 12 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Arjun Goyal last invest?
The most recent investment recorded for Arjun Goyal closed in Aug 2024. Shizune tracks 12 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
